BACKGROUND: In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin-releasing peptide (BN/GRP) on PC-3 human prostate cancers. METHODS: Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 microgram/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 microgram), BN/GRP antagonist RC-3940-II (10 microgram), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS: JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65% and 61%, respectively), but a combination of both antagonists augmented tumor inhibition to 75%. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92%), as compared with JV-1-38 (72%) or RC-3940-II (77%). Serum IGF-I concentration was lowered only in mice treated with JV-1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS: The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen-independent prostate cancer. Copyright 2000 Wiley-Liss, Inc.
BACKGROUND: In view of the involvement of various neuropeptides and growth factors in the progression of androgen-independent prostate cancer, we investigated the effects of antagonists of growth hormone-releasing hormone (GHRH) alone or in combination with an antagonist of bombesin/gastrin-releasing peptide (BN/GRP) on PC-3 humanprostate cancers. METHODS:Nude mice implanted with PC-3 tumors received GHRH antagonists MZ-5-156 or JV-1-38, each at 20 microgram/day s.c. In experiment 2, treatment consisted of daily injections of JV-1-38 (20 microgram), BN/GRP antagonist RC-3940-II (10 microgram), or a combination of JV-1-38 and RC-3940-II. Serum IGF-I levels, expression of mRNA for IGF-II, and characteristics of BN/GRP and EGF receptors in tumor tissue were investigated. RESULTS: JV-1-38 induced a greater inhibition of tumor growth and suppression of IGF-II mRNA than MZ-5-156, both compounds causing a similar decrease in serum IGF-I. In experiment 2, JV-1-38 and RC-3940-II produced a comparable reduction in tumor volume (65% and 61%, respectively), but a combination of both antagonists augmented tumor inhibition to 75%. Combined treatment with JV-1-38 and RC-3940-II also led to a greater suppression of IGF-II mRNA (92%), as compared with JV-1-38 (72%) or RC-3940-II (77%). Serum IGF-I concentration was lowered only in mice treated with JV-1-38, while the downregulation of BN/GRP and EGF receptors was specific for groups receiving RC-3940-II. CONCLUSIONS: The inhibitory effects of GHRH antagonists on PC-3 human androgen-independent prostate cancer can be potentiated by concomitant use of BN/GRP antagonists. The combination of both types of analogs apparently interferes with both IGF and bombesin/EGF pathways, and might be clinically useful for the management of androgen-independent prostate cancer. Copyright 2000 Wiley-Liss, Inc.
Authors: Gunhild Keller; Andrew V Schally; Kate Groot; Gabor L Toller; Alexandre Havt; Frank Köster; Patricia Armatis; Gabor Halmos; Marta Zarandi; Jozsef L Varga; Jörg B Engel Journal: Proc Natl Acad Sci U S A Date: 2005-07-18 Impact factor: 11.205
Authors: David J Merkler; Alexander S Asser; Laura E Baumgart; Natalie Carballo; Sarah E Carpenter; Geoffrey H Chew; Casey C Cosner; Jodi Dusi; Lamar C Galloway; Andrew B Lowe; Edward W Lowe; Lawrence King; Robert D Kendig; Paul C Kline; Robert Malka; Kathleen A Merkler; Neil R McIntyre; Mindy Romero; Benjamin J Wilcox; Terence C Owen Journal: Bioorg Med Chem Date: 2008-10-11 Impact factor: 3.641
Authors: Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga Journal: Proc Natl Acad Sci U S A Date: 2003-01-21 Impact factor: 11.205
Authors: Wellington K Hsu; Mandeep S Virk; Brian T Feeley; David B Stout; Arion F Chatziioannou; Jay R Lieberman Journal: J Nucl Med Date: 2008-02-20 Impact factor: 10.057
Authors: Celia A Kanashiro; Andrew V Schally; Kate Groot; Patricia Armatis; Andrea L F Bernardino; Jozsef L Varga Journal: Proc Natl Acad Sci U S A Date: 2003-12-05 Impact factor: 11.205
Authors: Rogier P J Schroeder; Cristina Müller; Suzanne Reneman; Marleen L Melis; Wout A P Breeman; Erik de Blois; Chris H Bangma; Eric P Krenning; Wytske M van Weerden; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-25 Impact factor: 9.236
Authors: Jian Guo; Andrew V Schally; Marta Zarandi; Jozsef Varga; Peter C K Leung Journal: Reprod Biol Endocrinol Date: 2010-05-28 Impact factor: 5.211
Authors: Rebeca Busto; Andrew V Schally; Jozsef L Varga; M Olga Garcia-Fernandez; Kate Groot; Patricia Armatis; Karoly Szepeshazi Journal: Proc Natl Acad Sci U S A Date: 2002-08-19 Impact factor: 11.205